HONG KONG, JEDDAH, 30 June 2025 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce that it has entered into an  exclusive license and supply agreement for the Company’s self-developed innovative drug Cyclosporine (“CsA”) Ophthalmic Gel (the “Product”) treating dry eye disease, with Jamjoom Pharmaceuticals Factory Company (“Jamjoom Pharma”), a leading Saudi pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products across Middle East & Africa (“MEA”).

Zhaoke Ophthalmology and Jamjoom Pharma entered into an exclusive license and supply agreement to commercialize CsA Ophthalmic Gel in the Middle East. Under the terms of the agreement, Zhaoke Ophthalmology grants Jamjoom Pharma the exclusive rights to register, import, distribute, promote, market, and sell CsA Ophthalmic Gel in countries including Saudi Arabia, the UAE, Bahrain, Kuwait, Oman, and Qatar. Zhaoke will receive certain payments based on specific achievements.

Zhaoke has also achieved other accomplishments for CsA Ophthalmic Gel recently. In early May 2025, a New Drug Application (“NDA”) for CsA Ophthalmic Gel was accepted for review by the National Medical Products Administration (“NMPA”) of China. Subsequently in early June 2025, the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for CsA Ophthalmic Gel as well.

With a strong focus on patient-centered care, Jamjoom Pharma serves diverse markets across MEA, with a bold ambition for more expansion, providing effective solutions in key therapeutic areas through thriving with continuous business development.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “We are thrilled about our partnership with Jamjoom Pharmaceuticals to bring our core drug CsA Ophthalmic Gel to the Middle East. This is our first out-licensing deal of Zhaoke’s in-house developed innovative drug, marking a significant milestone in our global expansion strategy and our commitment to advancing eye care and addressing unmet patient needs both at home and abroad. We look forward to more partnerships, bringing high-quality treatments to patients suffering from eye diseases worldwide.”

Dr. Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, commented: “At Jamjoom Pharma, everything we do begins with the patient. Our partnership with Zhaoke Ophthalmology to bring CsA Ophthalmic Gel to the Middle East and Africa is about more than a product—it’s about restoring comfort, clarity, and quality of life for the many people living with dry eye disease. Too often, patients in our region face limited options when it comes to effective eye care. This collaboration allows us to change that by delivering an advanced, clinically proven treatment that meets a real and growing need. We’re proud to expand access to innovation where it matters most, and we remain deeply committed to empowering patients with better solutions, better outcomes, and a better future.”

- End –